Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Novo Nordisk A/S (NVO)

Novo Nordisk A/S (NVO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 155,275,520
  • Shares Outstanding, K 2,354,800
  • Annual Sales, $ 18,291 M
  • Annual Income, $ 5,839 M
  • 60-Month Beta 0.46
  • Price/Sales 8.36
  • Price/Cash Flow 23.00
  • Price/Book 19.04

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/20
See More
  • Average Estimate 0.67
  • Number of Estimates 1
  • High Estimate 0.67
  • Low Estimate 0.67
  • Prior Year 0.61
  • Growth Rate Est. (year over year) +9.84%

Price Performance

See More
Period Period Low Period High Performance
1-Month
61.53 +7.17%
on 05/27/20
66.02 -0.12%
on 05/20/20
+2.90 (+4.60%)
since 04/29/20
3-Month
49.24 +33.92%
on 03/20/20
66.02 -0.12%
on 05/20/20
+7.81 (+13.44%)
since 02/28/20
52-Week
46.92 +40.54%
on 05/31/19
66.02 -0.12%
on 05/20/20
+18.91 (+40.21%)
since 05/29/19

Most Recent Stories

More News
Top Stock Reports for Novo Nordisk, IBM & Honeywell

Top Stock Reports for Novo Nordisk, IBM & Honeywell

SPGI : 325.02 (+1.95%)
NVO : 65.94 (+1.51%)
LOW : 130.35 (+1.74%)
IBM : 124.90 (+0.30%)
HON : 145.85 (-1.16%)
AMGN : 229.70 (+2.49%)
ALRT Diabetes Solution Complements President Trump's Initiative to Lower Insulin Costs and Drive Better Diabetes Care

On Tuesday, May 26, President Donald Trump announced a breakthrough program to cap the out of pocket cost of insulin to senior citizens on Medicare. The Trump administration is partnering with leaders...

LLY : 152.95 (+1.53%)
NVO : 65.94 (+1.51%)
ALRT : 0.0554 (+0.73%)
Thinking about trading stocks or options in Overstock.com, Novo Nordisk, Chegg, Tesla, or Netflix?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for OSTK, NVO, CHGG, TSLA, and NFLX.

CHGG : 61.08 (+1.01%)
NFLX : 419.73 (+1.52%)
NVO : 65.94 (+1.51%)
OSTK : 18.37 (+10.20%)
TSLA : 835.00 (+3.62%)
Coronavirus (COVID-19) Business Impact - New Research on Women Health Industry: Future of investment opportunities, market share & trends to 2027

MENAFN14052020007010847ID1100162919

ABT : 94.92 (+3.06%)
AGN : 193.02 (+0.02%)
AMGN : 229.70 (+2.49%)
BAYRY : 17.0999 (-0.76%)
LLY : 152.95 (+1.53%)
GSK : 41.92 (+0.91%)
NBIX : 124.76 (+3.78%)
NVS : 87.43 (+1.33%)
NOVN : 0.4030 (-1.42%)
NVO : 65.94 (+1.51%)
PFE : 38.19 (+0.03%)
RDUS : 12.66 (-5.03%)
TXMD : 1.1300 (-3.42%)
VRX.TO : 30.80 (-3.33%)
Evotec SE Reports First Quarter 2020 Results and Provides Corporate Update

Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) today announced the financial results and corporate updates for the first quarter 2020.

AMGN : 229.70 (+2.49%)
BMY : 59.72 (-0.15%)
EVTCY : 53.9500 (+0.84%)
NVS : 87.43 (+1.33%)
NVO : 65.94 (+1.51%)
Semaglutide 2.4 mg demonstrates superior and sustained weight loss versus placebo and in addition a 17.4% weight loss after 68 weeks in STEP 4 trial

Bagsvaerd, Denmark, 13 May 2020 - Novo Nordisk today announced headline results from STEP 4, the first completed phase 3a trial in the STEP programme. STEP 4 is a randomised, double-blind, multicentre,...

NVO : 65.94 (+1.51%)
The Global Smart Insulin Pen Market is expected to grow from USD 23.09 Million in 2018 to USD 63.89 Million by the end of 2025 at a Compound Annual Growth Rate (CAGR) of 15.64%

Reportlinker.com announces the release of the report "Global Smart Insulin Pen Market - Premium Insight, Competitive News Feed Analysis, Company Usability Profiles, Market Sizing & Forecasts to 2025" -...

LLY : 152.95 (+1.53%)
PODD : 188.57 (+2.16%)
NVO : 65.94 (+1.51%)
Ascendis Pharma A/S Will Appoint Jesper Høiland as Global Chief Commercial Officer

Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon(TM) technologies to address unmet medical needs, today announced that the company will appoint Jesper...

NVO : 65.94 (+1.51%)
RDUS : 12.66 (-5.03%)
ASND : 145.49 (-0.89%)
Global Anti-Diabetic Drugs Market (2020 to 2025) - Featuring AstraZeneca, Pfizer & Novo Nordisk Among Others

The "Anti-Diabetic Drugs Market - Forecasts from 2020 to 2025" report has been added to ResearchAndMarkets.com's offering.

NVO : 65.94 (+1.51%)
Pharma Stock Roundup: Q1 Earnings of BMY, NVO, Coronavirus Update From PFE, RHHBY

Novo Nordisk (NVO) and Bristol-Myers (BMY) announce Q1 results. Pfizer (PFE), Roche (RHHBY) and Lilly (LLY) provide update on their coronavirus-related research efforts.

NVO : 65.94 (+1.51%)
AZN : 54.60 (+2.06%)
RHHBY : 43.3500 (-1.37%)
PFE : 38.19 (+0.03%)
LLY : 152.95 (+1.53%)
NVS : 87.43 (+1.33%)
BMY : 59.72 (-0.15%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade NVO with:

Business Summary

Novo Nordisk is a world leader in insulin and diabetes care and also manufactures and markets a variety of other pharmaceutical products. Furthermore the company is the world's largest producer of industrial enzyme products. The company believes that everyone must care for the environment and our natural...

See More

Key Turning Points

2nd Resistance Point 67.01
1st Resistance Point 66.48
Last Price 65.94
1st Support Level 64.91
2nd Support Level 63.87

See More

52-Week High 66.02
Last Price 65.94
Fibonacci 61.8% 58.72
Fibonacci 50% 56.47
Fibonacci 38.2% 54.22
52-Week Low 46.92

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar